Crisaborole
- Generic Name
- Crisaborole
- Brand Names
- Eucrisa
- Drug Type
- Small Molecule
- Chemical Formula
- C14H10BNO3
- CAS Number
- 906673-24-3
- Unique Ingredient Identifier
- Q2R47HGR7P
- Background
Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older. It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile. Its structure contains a boron atom, which facilitates skin penetration and binding to the bimetal center of the phosphodiesterase 4 enzyme. It is currently under development as topical treatment of psoriasis.
- Indication
Intended for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.
- Associated Conditions
- Mild Atopic dermatitis, Moderate Atopic dermatitis
- Associated Therapies
- -
Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Applied Biology, Inc.
- Registration Number
- NCT05016284
- Locations
- 🇧🇷
Centro Universitário Nilton Lins, Manaus, Amazonas, Brazil
Response of Children With Atopic Dermatitis (Eczema) to Eucrisa
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2022-07-19
- Target Recruit Count
- 30
- Registration Number
- NCT04023084
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Steroid-reducing Effects of Crisaborole
- Conditions
- Interventions
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 24
- Registration Number
- NCT03832010
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Wearable Skin Sensors to Assess Nocturnal Scratch Behavior
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 23
- Registration Number
- NCT03770858
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 92
- Registration Number
- NCT03645057
- Locations
- 🇺🇸
University of Rochester Dermatology, Rochester, New York, United States
A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 30
- Registration Number
- NCT03567980
- Locations
- 🇺🇸
Dermatology at the Whitaker Clinic, Birmingham, Alabama, United States
Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Duke University
- Target Recruit Count
- 8
- Registration Number
- NCT03351114
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
Eucrisa for Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 28
- Registration Number
- NCT03250663
- Locations
- 🇺🇸
Wake Forest University Heath Sciences, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.